US Stock MarketDetailed Quotes

BIOA BioAge Labs

Watchlist

5.110
-0.220-4.13%

Close Jan 22 16:00 ET

5.130
+0.020+0.39%

Post 19:07 ET

183.19MMarket Cap-2.46P/E (TTM)

BioAge Labs Stock Forum

70065450

6 hours ago

$BioAge Labs (BIOA.US)$ institution is accumulating so just be patience

103753999

Yesterday 00:16

$BioAge Labs (BIOA.US)$ super slow and no volume

Pablovski

Jan 15 09:01

$BioAge Labs (BIOA.US)$ enough playing run the news

Jaguar8

Jan 13 20:52

Moomoo doesn’t have the news yet

$BioAge Labs (BIOA.US)$

Jaguar8

Jan 13 20:51

I’ll add this to picks tomorrow

$BioAge Labs (BIOA.US)$

74337002 : You got it wrong, it's BIIB and Eisai. Not bioa.

Report
Reply

Cancel Reply
74337002 : Hope you get more sleep, carefully study the Stocks before trading

Report
Reply

Cancel Reply
Jaguar8 OP 74337002 : 01/13/2025 - 06:49 PM
STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act (PDUFA) action date has been set to August 31, 2025.
The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If LEQEMBI subcutaneous maintenance dosing is approved by the FDA, LEQEMBI will be the only treatment for AD that can be administered subcutaneously at home using an autoinjector (AI). The injection process is expected to take, on average, 15 seconds. The SC-AI 360 mg weekly maintenance regimen will allow patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, to receive weekly doses that are expected to maintain the clinical and biomarker benefits.
The SC-AI is expected to be simple and easy for patients and their care partners to use, and may reduce the need for hospital or infusion site visits and nursing care for IV administration, which will make it easier to continue maintenance administration and may contribute to further simplifying the treatment pathway for AD.

Report
Reply

Cancel Reply
Jaguar8 OP 74337002 : I delivered the news which was released from BIOA. Eissa is not listed on Nasdaq nor NYSE Tell the BIOA that and not to me. I am not stupid.

Report
Reply

Cancel Reply
SJ24 : Based on my limited knowledge, pharma stocks tend to be very volatile. How do you manage that while also investing/trading in them?

Report
Reply

Cancel Reply

View more comments...

Jaguar8

Jan 13 20:50

NEWS

$BioAge Labs (BIOA.US)$
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
NEWS PROVIDED BY
BioArctic
Jan 13, 2025, 21:49 ET
STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingL...

Jaguar8

Jan 13 20:08

🔵 Watchlist JANUARY 14,2025, Tuesday. NFA. DO NOT ENTER without buy momentum.

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...

李飞Allyssa : Doctor, can you please take a look at LAES?

Report
Reply

Cancel Reply
Jaguar8 OP 李飞Allyssa : Sorry I forgot haha WKEY and LAES are together

Report
Reply

Cancel Reply
李飞Allyssa : Hope it rebounds tomorrow, thank you very much for your efforts

Report
Reply

Cancel Reply
152390662 : May I ask where did you see the announcement for $LeddarTech (LDTC.US)$

Report
Reply

Cancel Reply
Jaguar8 OP 152390662 : QUEBEC CITY, Canada, Jan. 13, 2025 (GLOBE NEWSWIRE) -- LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision, today announced it has wrapped up its presence at the 2025 Consumer Electronics Show (CES) and achieved key strategic milestones. The culmination of the event demonstrates that the company is poised to deliver exceptional value to its customers.
Driving Innovation Through Strategic Partnerships
With the successful CES 2025 demonstration of LeddarVision Surround (LVS-2+) software utilizing Texas Instruments (“TI”) TDA4VH-Q1 processor, LeddarTech has now received the second advanced royalty payment of US$ 3 million as part of its licensing agreement. This partnership, announced in early December 2024, aims to capitalize on the integration of LeddarTech’s groundbreaking LeddarVision software into TI’s scalable portfolio of processors to create a comprehensive platform for advanced driver assistance systems (ADAS) and autonomous driving (AD) markets. The collaboration signifies a pivotal step forward in delivering cutting-edge solutions to automotive OEMs and Tier 1 suppliers, underscoring LeddarTech’s commitment to innovation and leadership.
Customer and Partner Enthusiasm at CES 2025
At CES 2025 in Las Vegas, LeddarTech showcased its LeddarVision Surround-View (LVS-2+), a state-of-the-art software stack tailored for L2/L2+ highway and city ADAS applications. This breakthrough technology addresses critical challenges the automotive industry faces, setting new benchmarks in safety and performance and enabling automotive manufacturers to cost-effectively meet 5-star NCAP 2025/GSR 2022 requirements.

Report
Reply

Cancel Reply

View more comments...

Mcsnacks H Tupack

Jan 5 05:00

Crimes without criminals

The finance sector historically falls under this designation. One common theme you will hear traders exclaim is how they lost money due to some kind of illegal misrepresentation of facts occurring or by illegal trading methods.
In order for there to be a crash or a stock bubble, there has to have been a misrepresentation or for some type of fraud to have occurred. But who is to blame? The investor for driving up the value based on enthusiasm and not by the fundamentals? O...

kit6969

Dec 27, 2024 07:54

$BioAge Labs (BIOA.US)$ 🚀

Jaguar8

Dec 23, 2024 18:51

🔴Christmas Watchlist December 24,2024 😉. NFA. This is my last watchlist for the year

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on w...

Rumble shares continue to surge: Time to follow crypto money?